8
Jun
2018

BIO18 Reflections, Axovant and Ophthotech Reboot with Gene Therapy & More

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Amgen Swings for the RAS Fence, Gilead’s Grilling on Price, & Agios Enlarges the Pie
Thermo Bets on Viral Vector Manufacturing, Precision & Genfit’s IPOs, & Not Much Else
Sage’s Depression Triumph, Biogen’s Alzheimer’s Defeat, & Apple Watch Hype
Sharpless in the Saddle, NIH Threatened Again, & PBMs Prep for Senate Scrutiny